Vir Biotechnology, Inc. VIR · SEC Filings

367

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to...

Price13.645

Market Cap2.31 B

Float134.07 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWVir Biotechnology Announces Positive Phase 3 ECLIPSE 1 and Phase 2 SOLSTICE Results for Chronic Hepatitis Delta Treatment

Nov 9, 2026

8-K

Vir Biotechnology Reports Third Quarter 2026 Financial Results and Corporate Update

Nov 4, 2026

8-K

Vir Biotechnology Appoints Suzanne Topalian, M.D. to Board of Directors

Oct 28, 2026

8-K

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engag

Oct 14, 2026

8-K

Vir Biotechnology Announces FDA Fast Track Designation for Prostate Cancer Candidate VIR-5500

Oct 8, 2026

8-K

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Oct 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 26, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $200,000,000 | Bank: Goldman Sachs & Co. LLC

Feb 24, 2026

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Jul 8, 2020

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Oct 11, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 23, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2024

S-3ASR

SHELF | ATM | Offering amount: $300,000,000.00

Nov 3, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 14, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 19, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 8, 2020

CORRESP

Form CORRESP - Correspondence

Jul 6, 2020

CORRESP

Form CORRESP - Correspondence

Jul 6, 2020

LETTER

Form UPLOAD - SEC-generated letter

Jun 29, 2020

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 11, 2019

CORRESP

Form CORRESP - Correspondence

Oct 8, 2019